Cited 2 time in
Cited 2 time in
Comparative proteomic analysis of mouse models of pathological and physiological cardiac hypertrophy, with selection of biomarkers of pathological hypertrophy by integrative proteogenomics
- Comparative proteomic analysis of mouse models of pathological and physiological cardiac hypertrophy, with selection of biomarkers of pathological hypertrophy by integrative proteogenomics
- Kwon, Hye Kyeong; Jeong, Hyobin; Hwang, Daehee; Park, Zee-Yong
- DGIST Authors
- Hwang, Daehee
- Issue Date
- Biochimica et Biophysica Acta - Proteins and Proteomics, 1866(10), 1043-1054
- Article Type
- Biomarker; Cardiac hypertrophy; LC-MS/MS; Proteogenomics; Proteomics; actin depolymerizing factor; biological marker; cellular retinol binding protein 1; clusterin; collagen type 14; collagen type 14 alpha 1; elastin; fibronectin; fibronectin 1; fibulin; fibulin 2; myosin heavy polypeptide 9; nestin; plastin 3; protein; tenascin; unclassified drug; animal experiment; animal model; animal tissue; Article; controlled study; gene ontology; heart ventricle hypertrophy; male; mouse; mRNA expression level; nonhuman; priority journal; protein analysis; protein expression; proteogenomics; proteomics; transcriptomics; Western blotting
- To determine fundamental characteristics of pathological cardiac hypertrophy, protein expression profiles in two widely accepted models of cardiac hypertrophy (swimming-trained mouse for physiological hypertrophy and pressure-overload-induced mouse for pathological hypertrophy) were compared using a label-free quantitative proteomics approach. Among 3955 proteins (19,235 peptides, false-discovery rate < 0.01) identified in these models, 486 were differentially expressed with a log2 fold difference ≥ 0.58, or were detected in only one hypertrophy model (each protein from 4 technical replicates, p <.05). Analysis of gene ontology biological processes and KEGG pathways identified cellular processes enriched in one or both hypertrophy models. Processes unique to pathological hypertrophy were compared with processes previously identified in cardiac-hypertrophy models. Individual proteins with differential expression in processes unique to pathological hypertrophy were further confirmed using the results of previous targeted functional analysis studies. Using a proteogenomic approach combining transcriptomic and proteomic analyses, similar patterns of differential expression were observed for 23 proteins and corresponding genes associated with pathological hypertrophy. A total of 11 proteins were selected as early-stage pathological-hypertrophy biomarker candidates, and the results of western blotting for five of these proteins in independent samples confirmed the patterns of differential expression in mouse models of pathological and physiological cardiac hypertrophy. © 2018 Elsevier B.V.
- Elsevier B.V.
There are no files associated with this item.
- Department of New BiologySystems Biology and Medicine Lab1. Journal Articles
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.